Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organ Sparing for Locally Advanced Rectal Cancer After Neoadjuvant Treatment Followed by Electrochemotherapy (LARC_DEEP_CANCERS)
2024-519050-37-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bleomycin in rectal adenocarcinoma (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: Safety and feasibility and Complete histopathological response rate. Planned start Jan 2025; status: authorised.
02
Drugs
bleomycin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2024-519050-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519050-37-00.